Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer - Takeaways - MDSpire

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.

  • June 24, 2026

Share

  • 1

    Roswell Park is launching a Phase 1 clinical trial for GB-5267, an 'armored' CAR T-cell therapy targeting IL-18 in ovarian cancer patients.

  • 2

    GB-5267 is designed to target MUC16, enhance T cell activation, and recruit endogenous immune cells to improve treatment efficacy.

  • 3

    The therapy will be administered both intravenously and directly into the peritoneal cavity to concentrate the immune response.

  • 4

    GB-5267 is the first CAR T-cell therapy that does not require lymphodepletion, avoiding the adverse effects of chemotherapy.

  • 5

    The trial aims to provide a new treatment option for patients with relapsed or refractory ovarian cancer, which has limited existing therapies.

Original Source(s)

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

  • June 24, 2026

Related Content

Quercetagetin-rich flavonoids from marigold induce apoptosis inhibit metastasis of non-small cell lung cancer via the p53/p21 signaling pathway

A systematic review and meta-analysis of the effects of walking training on cardiorespiratory fitness in cancer patients

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study